Sandra Levy
ARTICLES BY THIS AUTHOR
- 2/22/2022
Walmart highlights COVID-19 vaccination successes in report
The COVID-19 One-Year Vaccine report outlines Walmart’s efforts to keep communities safe and healthy amid the pandemic. - 2/22/2022
Cosette debuts generic Compazine
The medication, which is the generic of Compazine, is used to control severe nausea and vomiting, as well as treat schizophrenia. - 2/22/2022
APhA announces student pharmacist award recipients
Honorees will be officially recognized at the APhA Annual Meeting and Exposition in San Antonio from March 18 to 21. - 2/22/2022
U.K.-based Boots pharmacy reportedly sets bid deadline
The sale reportedly will lead to the dismantling of the Walgreens Boots Alliance, which was set up in 2014 when Walgreens took full control of the health and beauty chain. - 2/22/2022
CVS Health intros home health products
The collection aims to bring functional and stylish products to the aging, caregivers and those living with disabilities, CVS Health said. - 2/21/2022
NACDS, Johns Hopkins Center for Health Security highlight pharmacy’s role in health equity
The “Striving Toward Health Equity in COVID-19 - The Role of Pharmacies in a National Response” initiative demonstrates the ways in which local pharmacies can be further leveraged to enhance equity for patients. - 2/21/2022
Walgreens Boots Alliance shares 2021 ESG report
The report highlights the company’s work in health and vaccine equity while also outlining the ongoing progress made on sustainability targets and initiatives. - 2/21/2022
Nexus gains FDA nod for generic Erythrocin
The medication is indicated in the treatment of infections caused by susceptible strains of designated organisms in certain diseases when oral administration is not possible. - 2/21/2022
GSK’s proposed health spinoff to be named Haleon
Haleon will have a world-class portfolio of category leading global brands, including Sensodyne, Voltaren, Panadol and Centrum, the company said. - 2/21/2022
Amneal receives FDA blessing for 4 generics
Amneal is introducing dexamethasone, azacitidine, carboprost and atropine for the institutional market.
